$A — AVOID 📊 | 6 MONTHS THESIS

🧭 Conviction: HIGH Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. 🎯 FQ2 FY2026 (ends Apr) | reported May 27 | Rev $1.8B | Adj EPS $1.49 vs $1.41 🟢 | GAAP op margin 21.7% 💡 The market expects continued beats and multiple expansion, but I see growth plateauing near guidance (6% top-line) and the P/E multiple contracting toward the sector median of 16x, aligning with historical norms for similar growers. 🏢 Business Quality: 7/10 📊 Valuation: rich — trailing non-GAAP P/E 23.1x vs peer median 16.0x; reverse DCF implies 6.4% FCF growth, which may be optimistic if growth decelerates;... 🔮 Catalyst: Q3 FY2026 earnings release ⚖️ Avoid: trading at 23x earnings versus peer median 16x, with modest growth and poor risk/reward; wait for a pullback to $105 or below before considering entry. 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/A0710

🧭 Conviction: HIGH